226 related articles for article (PubMed ID: 36067356)
1. Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy.
Fetse J; Zhao Z; Liu H; Mamani UF; Mustafa B; Adhikary P; Ibrahim M; Liu Y; Patel P; Nakhjiri M; Alahmari M; Li G; Cheng K
J Med Chem; 2022 Sep; 65(18):12002-12013. PubMed ID: 36067356
[TBL] [Abstract][Full Text] [Related]
2. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
[TBL] [Abstract][Full Text] [Related]
3. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
4. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.
Bojko M; Węgrzyn K; Sikorska E; Kocikowski M; Parys M; Battin C; Steinberger P; Kogut MM; Winnicki M; Sieradzan AK; Spodzieja M; Rodziewicz-Motowidło S
Bioorg Chem; 2022 Nov; 128():106047. PubMed ID: 35963023
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of α-helix-based peptide inhibitors for blocking PD-1/PD-L1 interaction.
Rui M; Zhang W; Mi K; Ni H; Ji W; Yu X; Qin J; Feng C
Int J Biol Macromol; 2023 Dec; 253(Pt 2):126811. PubMed ID: 37690647
[TBL] [Abstract][Full Text] [Related]
8. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
[TBL] [Abstract][Full Text] [Related]
9. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.
Wang T; Wu X; Guo C; Zhang K; Xu J; Li Z; Jiang S
J Med Chem; 2019 Feb; 62(4):1715-1730. PubMed ID: 30247903
[TBL] [Abstract][Full Text] [Related]
10. Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis.
Wang K; Song Y; Su Y; Liang Y; Wang L
Biochem Biophys Res Commun; 2020 Jun; 527(2):453-457. PubMed ID: 32336542
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
12. A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.
Shi YY; Dong DR; Fan G; Dai MY; Liu M
Front Immunol; 2023; 14():1237964. PubMed ID: 37849747
[TBL] [Abstract][Full Text] [Related]
13. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
[TBL] [Abstract][Full Text] [Related]
14. Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.
Magiera-Mularz K; Skalniak L; Zak KM; Musielak B; Rudzinska-Szostak E; Berlicki Ł; Kocik J; Grudnik P; Sala D; Zarganes-Tzitzikas T; Shaabani S; Dömling A; Dubin G; Holak TA
Angew Chem Int Ed Engl; 2017 Oct; 56(44):13732-13735. PubMed ID: 28881104
[TBL] [Abstract][Full Text] [Related]
15. Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy.
Yin H; Zhou X; Huang YH; King GJ; Collins BM; Gao Y; Craik DJ; Wang CK
J Am Chem Soc; 2021 Nov; 143(44):18536-18547. PubMed ID: 34661406
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
[TBL] [Abstract][Full Text] [Related]
18. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis.
Zyla E; Musielak B; Holak TA; Dubin G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443436
[TBL] [Abstract][Full Text] [Related]
19. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
Molecules; 2019 May; 24(11):. PubMed ID: 31151293
[TBL] [Abstract][Full Text] [Related]
20. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
